计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A125467-5mg |
5mg |
现货 ![]() |
| |
| A125467-10mg |
10mg |
现货 ![]() |
| |
| A125467-50mg |
50mg |
现货 ![]() |
|
| 英文别名 | SCHEMBL476278 | DTXSID80186513 | AB03409 | HMS2210M16 | AKOS016347360 | J-507662 | 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one | 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)- |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | AG14361 |
| 生化机理 | 据统计,AG14361在照射前处理可显著提高携带LoVo异种移植物的小鼠对放射治疗的敏感性。据统计,AG14361能明显增加异种移植物的血流量,从而有可能增加向肿瘤异种移植物输送drμg的量。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 聚(ADP-核糖)聚合酶 1 抑制剂 |
| 产品介绍 |
AG14361是PARP1抑制剂,Ki<5 nM,比苯甲酰胺的抑制性强1000倍。 AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one |
| INCHI | 1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24) |
| InChi Key | SEKJSSBJKFLZIT-UHFFFAOYSA-N |
| Smiles | CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O |
| Isomeric SMILES | CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O |
| 分子量 | 320.4 |
| Reaxy-Rn | 9283091 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9283091&ln= |
| 溶解性 | DMSO ≥20mg/mL Water <1.2mg/mL Ethanol ≥11mg/mL |
|---|---|
| 分子量 | 320.400 g/mol |
| XLogP3 | 1.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 320.164 Da |
| 单同位素质量Monoisotopic Mass | 320.164 Da |
| 拓扑极表面积Topological Polar Surface Area | 50.200 Ų |
| 重原子数Heavy Atom Count | 24 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 460.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, Webber SE, Eastman BW, Almassy R, Li J et al.. (2003) Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.. J Med Chem, 46 (2): (210-3). [PMID:12519059] |
| 2. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. (2003) Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.. Cancer Res, 63 (18): (6008-15). [PMID:14522929] |
| 3. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S et al.. (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.. J Natl Cancer Inst, 96 (1): (56-67). [PMID:14709739] |
| 4. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z et al.. (2004) Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.. Clin Cancer Res, 10 (3): (881-9). [PMID:14871963] |
| 5. Smith LM, Willmore E, Austin CA, Curtin NJ. (2005) The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.. Clin Cancer Res, 11 (23): (8449-57). [PMID:16322308] |
| 6. Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY. (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.. Nat Struct Mol Biol, 17 (10): (1247-54). [PMID:20871615] |
| 7. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.. Cancer Res, 72 (21): (5588-99). [PMID:23118055] |